ScholarGate
Asisten

Bandingkan metode

Tinjau metode pilihan Anda berdampingan; baris yang berbeda akan disorot.

Analisis Risiko Bersaing Adaptif×Desain Uji Adaptif×
BidangEpidemiologiPenelitian Klinis
KeluargaProcess / pipelineProcess / pipeline
Tahun asal1999 (foundational Fine-Gray model); adaptive extensions 2000s–2010s1990s-2000s
PencetusFine & Gray (subdistribution hazard, 1999); adaptive extensions by Beyersmann, Schumacher and colleaguesStephen Pocock, Christopher Jennison, and statistical methodologists; FDA formalized guidance 2019
TipeStatistical survival analysis with adaptive interim monitoringResearch Design
Sumber perintisFine, J. P., & Gray, R. J. (1999). A proportional hazards model for the subdistribution of a competing risk. Journal of the American Statistical Association, 94(446), 496–509. DOI ↗Pocock, S. J. (2005). Current issues in the design and interpretation of clinical trials. BMJ, 330(7500), 1118–1121. link ↗
Aliasadaptive Fine-Gray analysis, group-sequential competing risks, adaptive subdistribution hazard analysis, competing risks adaptive designadaptive trial, adaptive design, response-adaptive randomization, RAR
Terkait21
RingkasanAdaptive competing risks analysis combines the Fine-Gray subdistribution hazard framework — which models the cumulative incidence of one cause of failure in the presence of other mutually exclusive causes — with adaptive or group-sequential interim monitoring rules. This allows a clinical trial or observational study to be modified mid-course (e.g., sample size reassessment, early stopping) based on accumulating competing-risk data while maintaining pre-specified type I error control.An adaptive trial design allows pre-specified modifications to the trial based on interim data—such as sample size re-estimation, stopping for futility or efficacy, dropping ineffective arms, or shifting randomization ratios toward better-performing treatments. Developed systematically in the 1990s–2000s by statisticians like Pocock and Jennison, and formalized by the FDA in 2019, adaptive designs accelerate drug development, reduce exposure to ineffective treatments, and improve efficiency without inflating false-positive rates when properly executed.
ScholarGateSet data
  1. v1
  2. 2 Sumber
  3. PUBLISHED
  1. v1
  2. 3 Sumber
  3. PUBLISHED

Ke halaman pencarian Unduh salindia

ScholarGateBandingkan metode: Adaptive Competing Risks Analysis · Adaptive Trial Design. Diakses 2026-06-17 dari https://scholargate.app/id/compare